VJOncology is committed to improving our service to you

VJVirtual | ULTIMATE study: paclitaxel + bevacizumab in non-squamous NSCLC

VJOncology is committed to improving our service to you

Benjamin Besse

Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, discusses data coming from the ULTIMATE study. The study evaluated weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small cell lung cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter